Sugi Predict

Sugi Predict / Compounds / SCHEMBL244406

SCHEMBL244406

SCHEMBL244406

O=C(O)c1ccccc1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC5A2 P31639 5/20 0.64
▸ SLC5A1 P13866 2/20 0.64
▸ SLC28A3 Q9HAS3 2/20 0.60
▸ ATM Q13315 1/20 0.54
▸ TYR P14679 1/20 0.52
▸ HIF1A Q16665 1/20 0.52
▸ USP2 O75604 4/20 0.51
▸ HKDC1 Q2TB90 3/20 0.51
▸ L3MBTL1 Q9Y468 3/20 0.51
▸ TNNI3 P19429 2/20 0.51
▸ TNNT2 P45379 2/20 0.51
▸ TNNC1 P63316 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ GLA P06280 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14164007 1.00 SLC5A2 (0.64) SLC5A2SLC5A1SLC28A3ATMTYR
SCHEMBL8654092 1.00 SLC5A2 (0.64) SLC5A2SLC5A1SLC28A3ATMTYR
SCHEMBL4281885 1.00 SLC5A2 (0.64) SLC5A2SLC5A1SLC28A3ATMTYR
SCHEMBL29382560 1.00 SLC5A2 (0.64) SLC5A2SLC5A1SLC28A3ATMTYR
SCHEMBL28176940 1.00 SLC5A2 (0.64) SLC5A2SLC5A1SLC28A3ATMTYR
SCHEMBL8659653 1.00 SLC5A2 (0.64) SLC5A2SLC5A1SLC28A3ATMTYR
SCHEMBL8654543 1.00 SLC5A2 (0.64) SLC5A2SLC5A1SLC28A3ATMTYR
SCHEMBL7039100 0.90 SLC5A2 (0.56) SLC5A2SLC5A1SLC28A3ATMTYR
SCHEMBL1599039 0.90 SLC5A2 (0.56) SLC5A2SLC5A1SLC28A3ATMTYR
SCHEMBL941002 0.88 SLC28A3 (0.62) SLC5A2SLC5A1SLC28A3TYRHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0968221-B1 NOVEL SALICYLIC ACID DERIVATIVES AND THEIR USE IN COSMETIC OR DERMATOLOGICAL COMPOSITIONS OREAL (FR) 2003-05-02 — — EP claimed
US-6255297-B1 ANTIAGING AGENT L'OREAL (FR) 2001-07-03 — — US claimed
JP-59152328-A — — None — — JP disclosed
US-10004753-B2 Methods for treating tauopathy THE J. DAVID GLADSTONE INSTITUTES (US) 2018-06-26 — — US disclosed
US-20170368080-A1 METHODS FOR TREATING TAUOPATHY THE J. DAVID GLADSTONE INSTITUTES 2017-12-28 — — US disclosed
US-9205115-B2 Bacillus isolates and methods of their use to protect against plant pathogens and virus transmission MONTANA STATE UNIVERSITY (US) 2015-12-08 — — US disclosed
US-20140056864-A1 BACILLUS ISOLATES AND METHODS OF THEIR USE TO PROTECT AGAINST PLANT PATHOGENS AND VIRUS TRANSMISSION MONTANA STATE UNIVERSITY (US) 2014-02-27 — — US disclosed
US-8524222-B2 Bacillus isolates and methods of their use to protect against plant pathogens and virus transmission MONTANA STATE UNIVERSITY (US) 2013-09-03 — — US disclosed
US-8246965-B2 Bacillus isolates and methods of their use to protect against plant pathogens MONTANA STATE UNIVERSITY (US) 2012-08-21 — — US disclosed
US-20120003197-A1 BACILLUS ISOLATES AND METHODS OF THEIR USE TO PROTECT AGAINST PLANT PATHOGENS AND VIRUS TRANSMISSION MONTANA STATE UNIVERSITY (US) 2012-01-05 — — US disclosed
US-20110318386-A1 BACILLUS ISOLATES AND METHODS OF THEIR USE TO PROTECT AGAINST PLANT PATHOGENS MONTANA STATE UNIVERSITY (US) 2011-12-29 — — US disclosed
EP-1859835-A2 Topical agent for dermatological use containing 4-hydroxyphenyl-alpha-D-glucopyranoside PENTAPHARM Ltd. (CH) 2007-11-28 — — EP disclosed
US-20070224179-A1 Bacillus mycoides isolate that induces systemic resistance MONTANA STATE UNIVERSITY 2007-09-27 — — US disclosed
US-20030198610-A1 Topical agent for dermatological use DSM IP ASSETS B.V. (NL) 2003-10-23 — — US disclosed
EP-1289489-A2 TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE PENTAPHARM Ltd. (CH) 2003-03-12 — — EP disclosed
WO-2001091715-A2 TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE PENTAPHARM LTD. (CH) 2001-12-06 — — WO disclosed
US-6255297-B1 ANTIAGING AGENT L'OREAL (FR) 2001-07-03 — — US disclosed
US-5766267-A USING FIBER REACTIVE DYES HOECHST AKTIENGESELLSCHAFT (DE) 1998-06-16 — — US disclosed
EP-0745719-A2 Use of carbohydrate compounds as auxiliary agents in the dyeing or printing of fibrous materials HOECHST AKTIENGESELLSCHAFT (DE) 1996-12-04 — — EP disclosed
JP-S59152328-A ANALGESIC CONTAINING SALICYLIC ACID DERIVATIVE EISAI CO LTD 1984-08-31 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030198610-A1 Topical agent for dermatological use GALE, UGGT1, UGDH SLC5A2 1116/4885SLC5A1 1242/4885SLC28A3 2040/4885
US-10004753-B2 Methods for treating tauopathy MAPT, PYGB, CHAT SLC5A2 923/4885SLC5A1 645/4885SLC28A3 610/4885
US-20170368080-A1 METHODS FOR TREATING TAUOPATHY MAPT, PYGB, CHAT SLC5A2 923/4885SLC5A1 645/4885SLC28A3 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.